FDA Dupixent Warnings: A History of Label Updates and Safety Communications

Understanding the FDA warning history for Dupixent matters for two distinct purposes: helping current patients make informed treatment decisions with their physicians, and providing the evidentiary framework for failure-to-warn litigation, which turns on what was known when and whether warnings adequately reflected that knowledge. This guide traces the Dupixent labeling history and explains its legal significance.

Initial Approval and Original Label (2017)

Dupixent received its first FDA approval in March 2017 for adults with moderate-to-severe atopic dermatitis not adequately controlled with topical therapies. The original approval was based on clinical trial data showing significant efficacy and a generally favorable safety profile in trial populations. The initial labeling focused on the adverse reactions observed in clinical trials: injection site reactions, conjunctivitis, blepharitis, oral herpes, and eosinophilia.

Cancer was not a primary concern in the initial label because clinical trials are not well-powered to detect rare events like malignancies, and the follow-up periods in pre-approval trials were insufficient to capture long-term malignancy risks in a drug affecting immune function. This is an inherent limitation of the pre-approval clinical trial process for immunomodulating biologics — the real-world, long-term safety profile emerges through post-marketing surveillance after millions of patient-years of exposure.

Indication Expansions and Corresponding Label Updates

After the initial 2017 atopic dermatitis approval, the FDA approved Dupixent for additional indications through the Supplemental Biologics License Application (sBLA) process:

• October 2018: Approved as add-on maintenance therapy for adults with moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma
• June 2019: Atopic dermatitis indication expanded to adolescents aged 12 and older
• June 2020: Approved for adults with chronic rhinosinusitis with nasal polyps
• May 2022: Approved for atopic dermatitis in children aged 6 to 11
• May 2022: Approved for eosinophilic esophagitis in adults and adolescents aged 12 and older
• September 2022: Approved for prurigo nodularis in adults
• June 2024: Approved as an add-on maintenance treatment for adults with COPD with an eosinophilic phenotype

Each indication expansion extended the patient population on Dupixent to new disease groups and, in the pediatric atopic dermatitis expansions, to younger patients with longer potential treatment durations. From a pharmacovigilance standpoint, each expansion increased the total number of patient-years of exposure and thus the statistical power to detect rare adverse events in post-marketing data.

The Malignancy Signal and Label Updates

Case reports of lymphoma — particularly cutaneous T-cell lymphoma (CTCL) — in Dupixent-treated patients began appearing in medical literature from approximately 2019 onward. The signal was complicated by the diagnostic challenge of distinguishing early CTCL from severe atopic dermatitis, and by the known elevated baseline CTCL risk in the atopic dermatitis population. Despite these confounders, regulatory agencies and the medical community took the signal seriously.

In 2023, the European Medicines Agency required updates to Dupixent product information in Europe to include language about lymphoma cases observed in post-marketing. This regulatory action in Europe is relevant to US litigation because it demonstrates that the malignancy signal was considered significant enough by at least one major regulatory body to warrant label modification. European labeling updates do not automatically change US labeling, but they are evidence of what a regulatory body considered the appropriate warning level.

Current US Dupixent prescribing information (as of 2025–2026) includes warnings regarding malignancies under Section 5 (Warnings and Precautions). The label states that malignancies, including lymphoma, have been observed in clinical trials and post-marketing experience. It does not have a Boxed Warning for malignancy, which represents the FDA's current assessment that the evidence supports a Precautions-level warning rather than the highest warning designation.

Post-Marketing Studies and Safety Commitments

As a condition of various indication approvals, Sanofi and Regeneron are required to conduct post-marketing studies to further characterize safety signals identified pre-approval and in early post-marketing surveillance. These post-marketing study commitments (PMCs) represent the FDA's mechanism for getting additional safety data after approval without delaying patient access to effective treatments.

The existence of post-marketing study requirements for cancer risk characterization is itself legally significant: it demonstrates that the FDA identified the malignancy question as unresolved at the time of approval or indication expansion, and that additional evidence was considered necessary. In failure-to-warn litigation, plaintiffs can argue that the FDA's own requirement for additional cancer risk studies shows that patients and prescribers should have been informed more clearly that cancer risk was an open and actively monitored question during the period when they were making treatment decisions.

The FDA's CBE Process and Its Legal Significance

Drug manufacturers can update safety warnings in their prescribing information using a "Changes Being Effected" (CBE) filing — a mechanism that allows immediate label updates to add or strengthen safety warnings without waiting for full FDA review. The CBE process is specifically designed to allow manufacturers to add warnings quickly when new safety information becomes available. If post-marketing evidence suggests a safety concern, manufacturers can act immediately under CBE — they do not need to wait for the FDA to direct a label change.

In pharmaceutical failure-to-warn litigation, the CBE mechanism is important because it creates a legal question about when the manufacturer had sufficient information to warrant a CBE update and whether they acted on that information in a timely manner. Plaintiffs argue that when post-marketing evidence of malignancy risk was accumulating, the manufacturer had both the ability and the legal obligation to strengthen warnings promptly through CBE, and that the gap between the accumulation of safety evidence and label updates represents the failure-to-warn at the core of their claims.

What Current Patients Should Know About Their Prescribing Information

Patients who are currently on Dupixent or who were on it in the past and are now facing a cancer diagnosis should understand that the prescribing information available at the time of their prescribing may have been different from current prescribing information. FDA drug labels are periodically updated, and the specific version of the label that was in effect when a prescribing decision was made is the relevant document for evaluating what warnings a prescriber received.

FDA maintains a searchable database of historical prescribing information through DailyMed (dailymed.nlm.nih.gov). For patients building a legal record, obtaining the version of the Dupixent prescribing information that was current at the time their treatment began can help an attorney assess the warning-adequacy question.

How Warning History Affects Your Claim

Failure-to-warn claims in pharmaceutical litigation require establishing: that the risk existed; that the manufacturer knew or should have known about it; and that the warnings provided were inadequate relative to the known risk, resulting in harm to the plaintiff who would have acted differently with adequate warning. The warning history described above — the EMA's 2023 label update, ongoing post-marketing study requirements, and the FAERS signal — establishes that the malignancy risk was not unknown. Whether US labeling adequately conveyed that risk to prescribers and patients at each point in time is the central legal question for individual claims.

Related Pages on This Site

• Dupixent cancer risk overview
• Dupixent vs. other biologics safety
• Check your eligibility